StockNews.com Begins Coverage on Syros Pharmaceuticals (NASDAQ:SYRS)

StockNews.com began coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a research report report published on Sunday. The firm issued a sell rating on the stock.

A number of other research firms also recently commented on SYRS. TD Cowen reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 price objective (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Brookline Capital Management reissued a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.33.

Syros Pharmaceuticals Stock Up 4.1 %

Shares of Syros Pharmaceuticals stock opened at $0.17 on Friday. Syros Pharmaceuticals has a 52 week low of $0.16 and a 52 week high of $7.96. The firm’s 50 day moving average is $0.21 and its two-hundred day moving average is $1.49. The firm has a market capitalization of $4.68 million, a P/E ratio of -0.06 and a beta of 1.29.

Insider Buying and Selling at Syros Pharmaceuticals

In other news, Director Nancy A. Simonian sold 134,713 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the sale, the director now owns 41,070 shares in the company, valued at $11,088.90. This represents a 76.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 12.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Syros Pharmaceuticals

An institutional investor recently raised its position in Syros Pharmaceuticals stock. Exome Asset Management LLC lifted its position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) by 87.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 298,575 shares of the company’s stock after acquiring an additional 139,400 shares during the quarter. Exome Asset Management LLC owned 1.11% of Syros Pharmaceuticals worth $642,000 at the end of the most recent quarter. 91.47% of the stock is owned by hedge funds and other institutional investors.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.